CompletedPhase 4

Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

GermanyStarted 2002-09

Plain-language summary

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Positive skin prick test to house dust mite, * Positive RAST test to house dust mite, * Positive provocation test result to house dust mite, Exclusion Criteria: * Serious chronic diseases, * Other perennial allergies

Trial details

NCT IDNCT00263549

SponsorAllergopharma GmbH & Co. KG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-02

View on ClinicalTrials.gov More House Dust Mite Allergy trials